ReviewCell death discovery2025
O-GlcNAcylation in novel regulated cell death: ferroptosis, pyroptosis, and necroptosis.
Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GlcNAcylation, a dynamic post-translational modification involving the addition of N-acetylglucosamine to serine and threonine residues, has emerged as a key regulatory factor in cellular metabolism and signaling. Ferroptosis, pyroptosis, and necroptosis are newly discovered forms of regulated cell death that play crucial roles in various physiological and pathological processes, including cancer development, neurodegeneration, and inflammation. This review aims to summarize the functions of O-GlcNAcylation in modulating these distinct cell death pathways, with a focus on their implications in disease mechanisms and potential therapeutic applications. We summarize the mechanisms by which O-GlcNAcylation modulates ferroptosis, pyroptosis, and necroptosis, and explore the potential of targeting O-GlcNAcylation as a promising therapeutic strategy for diseases characterized by dysregulated cell death.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.